EVELO BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0005 USD | -98.77% |
|
-98.77% | -99.19% |
| May. 02 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Capitalization 1 | 413.3 | 130.3 | 558.4 | 324.5 | 176.5 |
| Enterprise Value (EV) 1 | 277.7 | 72.07 | 531.3 | 312.4 | 179.7 |
| P/E ratio | -4.67 x | -1.52 x | -5.1 x | -2.63 x | -1.23 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -4.94 x | -0.85 x | -5.91 x | -2.76 x | -1.69 x |
| EV / FCF | -8.65 x | -1.54 x | -13.1 x | -5.11 x | -2.94 x |
| FCF Yield | -11.6% | -65% | -7.61% | -19.6% | -34% |
| Price to Book | 3.02 x | 2.17 x | 18.8 x | 37.5 x | -35.8 x |
| Nbr of stocks (in thousands) | 1,588 | 1,604 | 2,309 | 2,673 | 5,481 |
| Reference price 2 | 260.2 | 81.20 | 241.8 | 121.4 | 32.20 |
| Announcement Date | 2/15/19 | 2/14/20 | 3/9/21 | 3/24/22 | 3/16/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -26.7 | -56.17 | -84.59 | -89.86 | -113.2 | -106.4 |
| EBIT 1 | -27.53 | -58.1 | -86.36 | -91.89 | -115.4 | -108.5 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -28.05 | -56.95 | -85.28 | -93.26 | -121.7 | -113.6 |
| Net income 1 | -28.05 | -56.95 | -85.47 | -93.67 | -122.2 | -114.5 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -182.0 | -55.67 | -53.37 | -47.45 | -46.18 | -26.28 |
| Free Cash Flow 1 | -15.63 | -32.12 | -46.85 | -40.41 | -61.1 | -61.02 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/5/18 | 2/15/19 | 2/14/20 | 3/9/21 | 3/24/22 | 3/16/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -27.66 | -32.71 | -27.56 | -28.74 | -29.59 | -29.05 | -21.09 | -24.9 | -19.57 |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -31.54 | -33.57 | -28.56 | -29.74 | -30.4 | -30.46 | -23 | -25.2 | -20.87 |
| Net income 1 | -31.6 | -33.73 | -28.65 | -29.86 | -30.56 | -30.56 | -23.54 | -25.34 | -21.1 |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | -11.80 | -12.60 | -10.80 | -11.20 | -8.000 | -5.600 | -3.400 | -4.600 | -3.780 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/29/21 | 10/28/21 | 3/24/22 | 5/12/22 | 8/11/22 | 11/14/22 | 3/16/23 | 5/15/23 | 8/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 3.2 |
| Net Cash position 1 | 28.3 | 136 | 58.2 | 27.1 | 12.1 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.0301 x |
| Free Cash Flow 1 | -15.6 | -32.1 | -46.9 | -40.4 | -61.1 | -61 |
| ROE (net income / shareholders' equity) | -160% | -68.5% | -86.7% | -207% | -624% | -6,233% |
| ROA (Net income/ Total Assets) | -55.2% | -35.7% | -43% | -63.3% | -80.8% | -89% |
| Assets 1 | 50.82 | 159.7 | 198.6 | 148.1 | 151.2 | 128.7 |
| Book Value Per Share 2 | -282.0 | 86.10 | 37.40 | 12.80 | 3.240 | -0.9000 |
| Cash Flow per Share 2 | 197.0 | 58.50 | 48.40 | 29.00 | 25.50 | 8.650 |
| Capex 1 | 1.74 | 5.46 | 3.03 | 1.32 | 1.52 | 0.62 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/5/18 | 2/15/19 | 2/14/20 | 3/9/21 | 3/24/22 | 3/16/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -99.19% | 9.49K | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- EVLO Stock
- Financials Evelo Biosciences, Inc.
